

C2
B2
B cont

phenyl, and wherein any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, in a pharmaceutically acceptable carrier, wherein said 5-androstene-3 β ,17 α - diol or ester or ether thereof is part of a cyclodextrin inclusion complex.

REMARKS

By the present amendment, claims 15 and 19 have been amended to delete reference to "a tumor proliferation inhibiting effective amount of". No new matter has been added.


Turning now to the Official Action mailed April 26, 2000, claims 15-20 are rejected under 35 U.S.C. §112, first paragraph, allegedly because the specification, does not reasonably provide enablement for the term "tumor proliferation". Applicants maintain that ample support may be found in the specification, and in the knowledge available to one of ordinary skill in the art, to practice the claim invention without the need for undue experimentation. Nevertheless, without conceding to the Examiner's arguments, in an effort to expedite prosecution these claims have been amended to remove the phrase "tumor proliferation" without prejudice or disclaimer, thus rendering this rejection moot.

Early and favorable consideration of the subject application is respectfully requested.

In the event that there are any questions concerning this amendment, or the application in general, the Examiner is respectfully urged to telephone the undersigned so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Malcolm K. McGowan
Registration No. 39,300

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: 24 January 2001